Close
Novotech
Jabsco PureFlo 21 Single Use

InterSystems Launches HealthShare Health Connect Cloud in AWS Marketplace

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.
- Advertisement -

InterSystems, a creative data technology provider dedicated to helping customers solve the most critical scalability, interoperability and speed problems, announced that HealthShare® Health Connect Cloud™, a high-performance healthcare integration engine, is available in AWS Marketplace. AWS Marketplace is a digital catalog with thousands of software listings from independent software vendors that make it easy to find, test, buy and deploy software that runs on Amazon Web Services (AWS).

HealthShare Health Connect Cloud is a scalable solution, serving the needs of healthcare delivery systems of all sizes – from small clinics to the world’s largest and most complex systems. With its availability in AWS Marketplace, customers can benefit from improved data automation and management capabilities, leading to enhanced patient outcomes.

AWS customers can now access HealthShare Health Connect Cloud’s platform-as-a-service (PaaS) offerings directly in AWS Marketplace. The PaaS solution delivers managed healthcare integration cloud services, providing high-volume transaction support, process management and monitoring to support mission-critical applications. With a simplified procurement process that includes flexible contract models, improved governance and control, license management and renewals, and custom pricing and terms, AWS customers can easily deploy HealthShare Health Connect Cloud and begin scaling data-driven applications on the cloud.

“Our operating system for health at home and integration with HealthShare HealthConnect Cloud allows healthcare organisations to deliver health-at-home, value-based care for the U.S. Medicare population,” said Ainar Abdrakhmanov, CEO, Pria. “With expanded accessibility and access to cloud-based, data-driven applications in AWS Marketplace, we can accelerate data automation and management capabilities to advance our mission of transforming chronic care management.”

“With HealthShare Health Connect Cloud in AWS Marketplace, we can extend our reach to hundreds of thousands of cloud-ready customers, powering accelerated healthcare data integration and true interoperability,” said Todd Sylvester, Director of Cloud Strategy, Execution, and Alliances of InterSystems. “At InterSystems, we streamline purchasing and onboarding to better support customers in their shift to the cloud and a digital-first healthcare approach.”

 

Latest stories

Related stories

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

CMC Bottleneck in Drug Development and IND Delays

Ask any experienced biopharma program manager what derails an IND filing most often, and the answer is rarely surprising: it is CMC. Not insufficient efficacy data, not toxicology surprises CMC. This article examines why Chemistry, Manufacturing, and Controls continues to be the most underestimated risk in early drug development, and what program leaders can do about it.

The Hidden Cost of Licensing in Biologic Drug Development

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »